Robust negotiations between biopharmaceutical companies and insurers often result in significant rebates and discounts. In 2018, nearly half of all spending on brand medicines went to entities other than the companies who researched, developed and manufactured the medicines.
However, unlike care received at an in-network hospital or physician’s office, negotiated discounts for medicines are not shared with patients with high deductibles or coinsurance. According to IQVIA, half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the full list price.
Insurers should share more of these rebates with patients at the pharmacy counter. Providing access to discounted prices at the point-of-sale could dramatically lower patients’ out-of-pocket costs.
Get the facts and find out where the discounts are going.
rebated back to payers and the supply chain
subject to a deductible that are abandoned at pharmacy
to non-biopharmaceutical company entities in the supply chain in 2020 alone